Also found in: Dictionary, Wikipedia.
Related to anastrozole: tamoxifen


an aromatase inhibitor used for treatment of advanced breast carcinoma in postmenopausal women; it inhibits conversion of circulating androgens into estrogens.



Pharmacologic class: Nonsteroidal aromatase inhibitor

Therapeutic class: Antineoplastic

Pregnancy risk category D


Reduces serum estradiol levels with no significant effect on adrenocorticoid or aldosterone level; decreases stimulating effect of estrogen on tumor growth


Tablets: 1 mg

Indications and dosages

Postmenopausal women with hormone receptor-unknown or hormone receptor-positive advanced breast cancer or with advanced breast cancer after tamoxifen therapy; adjuvant treatment for hormone receptor-positive breast cancer

Adults: 1 mg P.O. daily


• Hypersensitivity to drug or its components
• Women of childbearing age


Use cautiously in:
• ischemic heart disease
• breastfeeding patients
• children (safety and efficacy not established).


• Verify that patient isn't pregnant before giving drug.

Adverse reactions

CNS: headache, weakness, dizziness, depression, paresthesia, lethargy

CV: chest pain, peripheral edema, vasodilation, hypertension, thromboembolic disease

EENT: pharyngitis

GI: nausea, vomiting, diarrhea, constipation, abdominal pain, anorexia, dry mouth

GU: vaginal bleeding, leukorrhea, vaginal dryness, pelvic pain

Musculoskeletal: decreased bone mineral density, fractures, bone or back pain, muscle weakness

Respiratory: dyspnea, cough

Skin: rash

Other: food distaste, weight gain, swelling, hot flashes, flulike symptoms, tumor flare hypersensitivity reactions (including anaphylaxis, angioedema, urticaria)


Drug-diagnostic tests.Hepatic enzymes, low-density lipoproteins, total cholesterol: increased levels

Patient monitoring

Monitor patient closely for hypersensitivity reactions.
• Check regularly for signs and symptoms of thromboembolic disease, especially dyspnea and chest pain.
• Monitor for circulatory overload (suggested by peripheral edema, cough, and dyspnea).
• Assess for signs and symptoms of depression. Evaluate patient for suicidal ideation.
• Monitor liver function test results.

Patient teaching

Instruct patient to immediately notify prescriber if signs and symptoms of hypersensitivity occur (such as itching or swelling of face, lips, or throat).

Advise patient to immediately report signs and symptoms of thromboembolic disease and circulatory overload.
• Emphasize importance of preventing pregnancy during therapy.
• Tell patient to contact prescriber if she develops signs or symptoms of depression.
• Caution patient to avoid driving and other hazardous activities until she knows how drug affects concentration and alertness.
• Advise patient to minimize GI upset by eating small, frequent servings of food and drinking plenty of fluids.
• Inform patient that she'll undergo regular blood testing during therapy.
• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the tests mentioned above.


/anas·tro·zole/ (ah-nas´trah-zōl″) an antineoplastic used for treatment of advanced breast carcinoma in postmenopausal women.


a nonsteroidal aromatase inhibitor.
indication It is prescribed in the treatment of advanced breast cancer for postmenopausal women whose disease has not responded to treatment with tamoxifen.
contraindication The drug is usually effective only in patients with estrogen-dependent tumors.
adverse effects The side effects most often reported include diarrhea, fatigue, nausea, headache, hot flashes, and back pain.


An aromatase inhibitor, which converts androstenedione to estradiol in peripheral fat.
Postmenopausal women with advanced oestrogen-dependent breast cancer that does not respond to tamoxifen; unlike tamoxifen, anastrozole is not associated with increased risk of endometrial cancer.


An anti-oestrogen drug. Anastrozole is an aromatase-inhibitor anti-estrogen drug used in the treatment of advanced breast cancer in post-menopausal women. An aromatase is an enzyme that promotes the conversion of testosterone to the aromatic compound oestradiol (estradiol). This process occurs in women, and its inhibition can reduce oestrogen levels which can be helpful in the control of oestrogen-dependent tumours. The side effects may include any of those due to oestrogen deficiency. A brand name is Arimidex.
References in periodicals archive ?
However, anastrozole worked better against hormone-dependent cancers, says study coauthor Aman U.
1 FALCON is a randomized, double-blind, parallel group, multicenter, Phase III study evaluating the efficacy and tolerability of fulvestrant 500 mg (monotherapy) compared to anastrozole 1 mg (monotherapy) as hormonal treatment for postmenopausal women with hormone receptor-positive locally advanced or metastatic breast cancer who have not previously been treated with any hormonal therapy.
AIs such as anastrozole, letrozole and exemestane almost completely inhibit the action of the enzyme aromatase, which is required for the peripheral conversion of testosterone and androstenedione to oestrogen (the final step in the oestrogen biosynthesis pathway) [19].
The meta-analysis included six randomized, tamoxifen-controlled clinical trials of anastrozole and two of letrozole totalling 18,548 postmenopausal breast cancer patients.
New data from ATAC(x), one of the world's largest and longest-running studies in postmenopausal women with hormone receptor positive (HR+), early breast cancer, reinforce that anastrozole can help many more women live cancer-free, for longer.
Anastrozole is already used as a treatment for women who have breast cancer, and doctors believe it could be successful in staving off the onset of the disease.
Until now anastrozole, which is made under the brand Arimidex by Cheshire-based pharmaceutical company AstraZeneca, has only been available on the NHS to a restricted number of women with specific health problems.
Experts claim the drug, anastrozole, is the next big step in fighting the disease which kills more than 13,000 women in the UK each year.
Yesterday, they launched a 10-year study of anastrozole, involving 10,000 healthy but high-risk women.
Anastrozole is licensed in the UK to treat advanced cancer only.
AstraZeneca (NYSE: AZN) today announced its first-ever direct-to-patient program offering patients with a valid prescription for ARIMIDEX or anastrozole the opportunity to have the brand ARIMIDEX delivered directly to their home by Express Scripts, a specialty pharmacy services provider, for $40 per month, including shipping.
announced today that they will launch Anastrozole 1mg Tablets.